Predictors of premature gonadal failure in patients with systemic lupus erythematosus. Results from LUMINA, a multiethnic US cohort (LUMINA LVIII)

Annals of the Rheumatic Diseases

Volumn 67, Issue 8, 2008, Pages 1170-1173

  Gonzalez L A ^a   McGwin Jr , G ^b   Duran S ^a   Pons Estel, G J ^a   Apte, M ^a   Vila L M ^c   Reveille, J D ^d   Alarcon G S ^a,b,e  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ARTICLE; CONFIDENCE INTERVAL; DISEASE ACTIVITY; ETHNICITY; FEMALE; GONAD DYSFUNCTION; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RATING SCALE; SYSTEMIC LUPUS ACTIVITY MEASURE REVISED; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS INTERNATIONAL COLLABORATING CLINIC DAMAGE INDEX; UNIVARIATE ANALYSIS;

ACUTE DISEASE; ADULT; AFRICAN AMERICANS; AGE FACTORS; CYCLOPHOSPHAMIDE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MENOPAUSE, PREMATURE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK;

EID: 47949085103     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.083436     Document Type: Article

References (18)

1. Boumpas DT, Austin HAI, Vaughn EM, Yarboro CH, Klippel JH, Balow JE. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993;119:366-9.
2. McDermott EM, Powell RJ. Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide. Ann Rheum Dis 1996;55:224-9.
3. Mok CC, Lau CS, Wong RW. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum 1998;41:831-7.
4. Moncayo R, Moncayo HE. Autoimmunity and the ovary. Immunol Today 1992;13:255-8.
5. Pasoto SG, Viana VS, Mendonca BB, Yoshinari NH, Bonfa E. Anti-corpus luteum antibody: a novel serological marker for ovarian dysfunction in systemic lupus erythematosus? J Rheumatol 1999;26:1087-93.
6. Fernandez M, Alarcon GS, Calvo-Alen J, Andrade R, McGwin G Jr, Vila LM, et al. A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Rheum 2007;57:576-84.
7. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the systemic lupus international collaborating clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-9.
8. Ioannidis JP, Katsifis GE, Tzioufas AG, Moutsopoulos HM. Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus. J Rheumatol 2002;29:2129-35.
9. Pasoto SG, Mendonca BB, Bonfa E. Menstrual disturbances in patients with systemic lupus erythematosus without alkylating therapy: clinical, hormonal and therapeutic associations. Lupus 2002;11:175-80.
10. Silva CA, Hilario MO, Febronio MV, Oliveira SK, Terreri MT, Sacchetti SB, et al. Risk factors for amenorrhea in juvenile systemic lupus erythematosus (JSLE): a Brazilian multicentre cohort study. Lupus 2007;16:531-6.
11. Alarcon GS, Friedman AW, Straaton KV, Moulds JM, Lisse J, Bastian HM, et al. Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. LUpus in Minority populations: NAture vs. Nurture. Lupus 1999;8:197-209.
12. Toloza SMA, Roseman JM, Alarcón GS, McGwin G Jr, Uribe AG, Fessier BJ, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) XXII: Predictors of time to the occurrence of initial damage. Arthritis Rheum 2004;50:3177-86.
13. Vilá LM, Alarcón GS, McGwin G Jr, Friedman AW, Baethge BA, Bastian HM, et al. Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations. Rheumatology (Oxford) 2004;43:358-63.
14. Takada K, Arefayene M, Desta Z, Yarboro CH, Boumpas DT, Balow JE, et al. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum 2004;50:2202-10.
15. Testa G, Chiaffarino F, Vegetti W, Nicolosi A, Caliari I, Alagna F, et al. Case-control study on risk factors for premature ovarian failure. Gynecol Obstet Invest 2001;51:40-3.
16. Meirow D, Lewis H, Nugent D, Epstein M. Subclinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool. Hum Reprod 1999;14:1903-7.
17. Andre M, Delevaux I, Amoura Z, Corbi P, Courthaliac C, Aumaitre O, et al. Ovarian vein thrombosis in the antiphospholipid syndrome. Arthritis Rheum 2004;50:183-6.
18. Shoenfeld Y, Blank M. Autoantibodies associated with reproductive failure. Lupus 2004;13:643-8.